Comparison of two diagnostic algorithms for the identification of patients with HCV Viremia using a new HCV antigen test

Annals of Hepatology

Volumn 13, Issue 3, 2014, Pages 337-342

  Reyes Méndez, Miguel Ángel ^a   Juárez Figueroa, Luis ^b   Iracheta Hernández, Patricia ^b   Medina Islas, Yasmín ^b   Ruiz González, Verónica ^b  

^a Scientific Affairs Abbott Diagnostics   (Mexico)

^b Clínica Especializada Condesa Iztapalapa   (Mexico)

Author keywords

Anti HCV antibodies; Diagnostic tests; Diagnostic tests and procedures; Hepatitis C virus

Indexed keywords

HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HCV CORE ANTIGEN TEST; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SIMULATION; VIREMIA; VIRUS LOAD; ALGORITHM; BLOOD; COST BENEFIT ANALYSIS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY;

ALGORITHMS; COST-BENEFIT ANALYSIS; DNA, VIRAL; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIREMIA;

EID: 84901402088     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30862-2     Document Type: Article

References (11)

1. World Health Organization. Hepatitis C: Fact Sheet No. 164. World Health Organization 2011. Available at: http:// www.who.int/mediacentre/factsheets/fs164/en/ index.html
2. Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, et al. Trends and Projections of Hepatitis C epidemiology in Latin America. Liver International 2011; 31: S18-S29.
3. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, et al. An assay for circulating antibodies to a major etiologic virus of non A non B hepatitis. Science 1989; 244: 362-4.
4. Cornish N. Laboratory diagnosis and evaluation of treatment for HCV. College of American Pathologists. CAP Today 2005; 78.
5. Albeldawi M, Ruiz-Rodriguez E, Carey WD. Hepatitis C virus, prevention, screening and interpretation of assays. Cleve Clin J Med 2010; 77: 616-626.
6. Hosseini-Moghaddam SM, Iran-Pour E, Rotstein C, Husain S, Lilly L, Renner E, Mazulli T. Heptitis C core antigen and its clinical applicability: Potential advantages and disadvantages for diagnosis and follow up. Rev Med Virol 2012; 22: 156-65.
7. Medici MC, Furlini G, Rodella A, Fuentes A, Monachetti A, Calderaro A, Galli S, et al. Hepatitis C virus core antigen: analytical performance, correlation with viremia and potential applications of a quantitative automated assay. J Clin Virol 2011; 51: 264-269.
8. Ghany MG, Strader DB, Thomas DL, Seef LB, American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
9. Alter MJ, Kuhnert WL, Finelli L. Guidelines for Laboratory Testing and Result Reporting of Antibody to Hepatitis C Virus. Morbidity and Mortality Weekly Report 2003; 52; 1-16.
10. Contreras AM, Ochoa-Jiménez RJ, Celis A, Méndez C, Olivares L, Rebolledo CE, Hernandez-Lugo I, et al. High Antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection. Transfusion 2010; 50: 1335-1343. Doi: 10.1111/j.1537-2995.2009. 02571.x.
11. Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, et al. Performance and Clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009; 46: 210-215.